

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290

Status	RECRUITING
Phase	Phase 2
Sponsor	Novartis Pharmaceuticals
Enrollment	126 participants

Key Eligibility Criteria

Inclusion (3)

- Men and women, aged e18 and d 75 years with a diagnosis of GPA or MPA according to the American College of Rheumatology/ European League Against Rheumatism 2022 (ACR/EULAR 2022) classification criteria
- Positive test for ANCA-autoantibodies
- GPA and MPA participants with severe active disease

Exclusion (5)

- Any condition that could prevent a complete washout of medications or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study
- Hypersensitivity and/or contraindications to any product to be given to the participant as part of the study protocol
- Other systemic autoimmune diseases requiring therapy
- Any medical conditions that are not related to GPA/MPA that would jeopardize the ability of the participant to tolerate CD19 CAR-T cell therapy
- Inadequate organ function

Locations (31 total)

University Of Colorado, Aurora, Colorado, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Northwestern University, Chicago, Illinois, United States
... and 28 more locations